Physician profile
Arjun Makam
NPI 1669732749
$13,434.17
in general payments reported to CMS, 2019-2025
32 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,683 · 2021: $2,645 · 2022: $2,266 · 2023: $1,947 · 2024: $2,007 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,788 · Education: $52.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,787.90 |
| Education | $52.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,234.29 | 2019-2025 | Varithena Administration Pack, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $1,712.95 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $1,206.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $999.29 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Edwards Lifesciences Corporation | $843.29 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Esperion Therapeutics, INC. | $817.57 | 2021-2025 | Nexletol |
| Amgen INC. | $801.63 | 2021-2025 | Repatha, Repatha, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $734.36 | 2021-2025 | |
| Novo Nordisk INC | $706.67 | 2021-2025 | Ozempic, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $530.54 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $491.65 | 2021-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $377.04 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.54 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $288.90 | 2021-2025 | Verquvo, Capvaxive |
| Lilly USA, LLC | $214.32 | 2021-2024 | Mounjaro, Zepbound |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $162.43 | 2021 | |
| Kestra Medical Technology Services, INC. | $129.64 | 2022-2025 | Assure Wcd |
| Lantheus Medical Imaging, INC. | $129.41 | 2019 | |
| Cardiovascular Systems INC. | $101.24 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $89.35 | 2021-2022 | |
| Amarin Pharma, INC. | $88.49 | 2021-2022 | |
| Medtronic Vascular, INC. | $84.49 | 2019 | |
| Medtronic, INC. | $81.35 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $55.55 | 2023-2025 | Evkeeza |
| Medicure Pharma INC. | $40.74 | 2021 | |
| Scpharmaceuticals INC. | $40.55 | 2023 | |
| Atricure, INC. | $37.26 | 2022 | |
| Abiomed | $24.68 | 2025 | |
| Heartflow, INC. | $24.60 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.28 | 2022 | |
| Baxter Healthcare | $22.14 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Biohaven Pharmaceuticals, INC. | $20.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Makam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.